Metabolic syndrome (MetS) is a global health concern characterized by a cluster of conditions, including obesity, insulin resistance, dyslipidemia, and hypertension, significantly increasing the risk of cardiovascular diseases and type 2 diabetes. Emerging research highlights the gut microbiome as a critical player in MetS, with gut dysbiosis—an imbalance of microbial communities—exacerbating metabolic dysfunction through inflammation and impaired metabolic pathways. This chapter explores current and innovative pharmacological therapies targeting the gut microbiome to restore microbial balance and improve metabolic outcomes. Therapeutic strategies such as prebiotics, probiotics, synbiotics, and postbiotics are discussed for their role in enhancing gut health by modulating gut microbiota composition, improving insulin sensitivity, and reducing systemic inflammation. Advanced therapies, including bacterial consortia, phage therapy, and next-generation probiotics, offer promising, targeted approaches to mitigate MetS’s impacts by restoring metabolic homeostasis. This comprehensive review also highlights the potential of precision microbiome-targeted therapies in treating MetS and underscores the need for further clinical research to optimize therapeutic outcomes.